Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819103 | 1.00 | NR1I2 (0.38) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL21101056 | 1.00 | NR1I2 (0.38) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL20372779 | 0.98 | NR1I2 (0.37) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL20098207 | 0.98 | NR1I2 (0.37) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL19198110 | 0.98 | NR1I2 (0.37) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL9228623 | 0.96 | NR1I2 (0.36) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL9784828 | 0.95 | NR1I2 (0.42) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL21143064 | 0.95 | NR1I2 (0.42) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL4650546 | 0.95 | NR1I2 (0.42) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL10633531 | 0.95 | NR1I2 (0.42) | NR1I2GPR84CSNK1ECYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | NR1I2 3634/4885GPR84 825/4885CSNK1E 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.